User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8506

Interactions with Platform & by Email *

INTERACTIONS

1191

Unique # Participated *

PARTICIPANTS

255

Responses Validated *

VALIDATIONS

48

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Introduction.....II-1
Hypertension – Prevalence.....II-1
Market Overview.....II-1
1$100
   Current and Future Analysis.....II-2
ARBs Lead the World Anti-hypertension Drugs Market.....II-2
Lack of R&D Innovation, Genericization Characterize the Global Anti-Hypertensive Drugs
  Market.....II-2
2$200
   Definition.....II-4
Blood Pressure.....II-4
High Blood Pressure.....II-4
Concerns.....II-4
Consequences.....II-4
1$100
   Hypertension and Diabetic Population.....II-5
Categorization.....II-5
Primary and Secondary Hypertension.....II-5
Acute Hypertension.....II-5
Diagnosis.....II-5
1$100
   Treatment.....II-6
Lifestyle Modifications.....II-6
Avoiding Nicotine Products.....II-6
Avoiding Alcohol.....II-6
Avoiding Processed Foods.....II-6
Restricting Sodium.....II-6
Reducing Weight.....II-6
1$100
   Adopting Biofeedback / Relaxation Techniques.....II-7
Anti-Hypertensive Drugs.....II-7
Beta Blockers.....II-7
Types of Beta-blockers.....II-7
1$100
   Calcium Channel Blockers.....II-8
Types of Calcium Channel Blockers.....II-8
Angiotensin II Receptor Blockers.....II-8
Types of Angiotensin II Receptor Blockers.....II-8
1$100
   ACE Inhibitors.....II-9
Types of ACE Inhibitors.....II-9
Diuretics.....II-9
1$100
   Types of Diuretics.....II-10
Other Anti-hypertensive Drugs.....II-10
Renin Inhibitors.....II-10
Vasodilators.....II-10
1$100
   Types of Vasodilators and Brand Names.....II-11
Alpha Blockers.....II-11
Mixed Blockers.....II-11
Adrenergic Receptor Agonist.....II-11
Aldosterone Receptor Antagonists.....II-11
Central Alpha Agonists.....II-11
1$100
   Side Effects.....II-12
Side Effects by Drug Class.....II-12
Thiazide Diuretics.....II-12
Beta-blockers.....II-12
ACE Inhibitors.....II-12
Peripheral Vasodilators.....II-12
1$100
   Side Effects by Drug Name.....II-13
Side Effects Profile of Select Anti-hypertensive Drugs.....II-13
1$100
   Select Leading Anti-hypertensive Drugs: A Review.....II-14
Benicar/Olmetec.....II-14
Cleviprex.....II-14
1$100
   Cozaar.....II-15
Diovan/Diovan HCT.....II-15
Exforge.....II-15
Norvasc.....II-15
Tekturna/Rasilez.....II-15
1$100
   Tekturna HCT.....II-161$100
   Takeda’s TAK-536 Reaches Phase III Clinical Trials in Japan.....II-17
China Pharma Commences Clinical Trials for Candesartan Generic.....II-17
Taipei Medical University Reveals Results of New Blood Pressure Study.....II-17
Researchers Identify New Genes Affecting Blood Pressure.....II-17
1$100
   Italian Study Demonstrates Benefits of Investigational Amlodipine and Telmisartan
  Combination Treatment in Blood Pressure Patients Exposed to Risk of Cardiovascular
    Events.....II-18
Gilead Sciences Announces Phase III Darusentan Data.....II-18
1$100
   Gilead Sciences Commences Phase II Trial of Cicletanine.....II-19
New Clinical Data Demonstrates Effectiveness of Rasilez/ Tekturna in Obese Patients
  with Hypertension in Comparison to Monotherapy with Diuretic
    Hydrochlorothiazide.....II-19
New Study Demonstrates Effectiveness of Exforge® in Controlling High Blood Pressure in
  "difficult-to-treat" Patients than Amlodipine Alone.....II-19
New Analyses Demonstrates Use of Cleviprex for Controlling Perioperative Hypertension
  to Lower the Risk of Heart Attack and Mortality Following Cardiac Surgery.....II-19
Surface Logix Announces Encouraging Phase IIa Results of SLx-2101.....II-19
1$100
   Observational Study Demonstrates Telmisartan to Provide Powerful Blood Pressure Control
  for Complete 24-hours, Including the Risky Hours of Early Morning.....II-20
New Study Demonstrates Tekturna® When Combined with Diovan® to Have Additional Blood
  Pressure Lowering Effect.....II-20
1$100
   Protherics Develops High Blood Pressure Vaccine.....II-211$100
   Takeda Introduces ECARD for Hypertension Treatment.....II-22
Amneal Pharmaceuticals Introduces Benazepril HCI.....II-22
Ranbaxy Laboratories to Introduce Daiichi Sankyo's Olvance in India.....II-22
Gemini Pharmaceuticals Launches Anti-hypertensive Medicine, Micardis.....II-22
1$100
   Shionogi Introduces Fluitran® 1mg.....II-23
Helvepharm Launches New Anti-hypertensive Drug.....II-23
Ranbaxy Laboratories Introduces Amlodipine.....II-23
Nicholas Piramal Launches Hypertension Management Device.....II-23
GlaxoSmithKline Introduces Ambrisentan.....II-23
Novartis Introduces Aliskiren.....II-23
1$100
   Dainippon Introduces Avapro for Hypertension Treatment.....II-24
Shionogi Introduces Irbetan for Hypertension Treatment.....II-24
Pfizer Japan Introduces Sildenafil.....II-24
Surgipharm Launches Diovan and Co-diovan.....II-24
King Pharmaceuticals Introduces Altace Tablets.....II-24
Encysive Pharmaceuticals Introduces Thelin Tablets.....II-24
Dr Reddy's Laboratories Introduces Atocor-R.....II-24
1$100
   Wockhardt to Introduce Amlodipine Tablets.....II-25
GlaxoSmithKline Launches Coreg CR Extended- Release Capsules.....II-25
Toray and Astellas Introduce Careload LA Tablets.....II-25
Encysive Introduces Sitaxentan Encysive.....II-25
GlaxoSmithKline Introduces Carzec.....II-25
Encysive Pharmaceuticals Introduces Thelin.....II-25
1$100
   Ranbaxy Laboratories Introduces Generic Drug Verapamil.....II-26
Actavis Group Introduces NIFEdipine (XR) Tablets.....II-26
Apotex Introduces Norvasc Generic.....II-26
Novartis Introduces Aliskiren.....II-26
Encysive Introduces Sitaxentan.....II-26
Pfizer to Release the Generic Version of Norvasc.....II-26
Mylan Introduces Generic Blood Pressure Medicines.....II-26
1$100
   Sanofi-Aventis Takes Over Helvepharm.....II-27
ARCA Biopharma Merges with Nuvelo.....II-27
Astellas and Nippon Receive Approval for Micombi® Antihypertensive Drug.....II-27
The Medicines Co Announces EU Acceptance of MAA for Cleviprex.....II-27
1$100
   Actelion and GeneraMedix Sign Definitive Agreement.....II-28
AtCor Medical Enters into Contract with Pharmaceutical Company.....II-28
Ranbaxy Receives FDA Approval for Anti- hypertensive Drug.....II-28
Sun Pharmaceuticals Receives Approval for Generic Version of Accupril.....II-28
Sucampo Pharma Americas Wins Rights to Rescula.....II-28
1$100
   Novartis Obtains Approval from Japanese Health Ministry.....II-29
Novartis Obtains FDA Approval for Exforge HCT.....II-29
Novartis Obtains Approval for Four New Medicines.....II-29
1$100
   Aveva Drug Delivery Obtains Approval for Clonidine TDS.....II-30
Ranbaxy Receives Approval to Market Anti- Hypertension Drug.....II-30
Actelion Receives FDA Approval for New Ventavis Formulation.....II-30
Sinobiopharma Receives Chinese Approval for Perindopril.....II-30
1$100
   Pfizer Acquires Encysive Pharmaceuticals.....II-31
GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business.....II-31
Gilead Sciences Acquires Navitas’ Cicletanine Business Assets.....II-31
Shionogi Acquires Sciele Pharma.....II-31
1$100
   Recordati Acquires Yeni Ilac.....II-32
Kyowa Hakko Merges with Kirin Pharma.....II-32
Belupo and Farmavita Announce Merger.....II-32
Daiichi Sankyo India and GlaxoSmithKline Sign Co-Promotion Deal.....II-32
1$100
   Sciele Pharma and Addrenex Pharmaceuticals Sign Exclusive Agreement.....II-33
Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb.....II-33
Forest Laboratories Holdings Amends Agreement with Mylan.....II-33
Speedel Secures FDA Approval for Tekturna HCT.....II-33
1$100
   Lupin Receives FDA Approval for Generic Ramipril Capsules.....II-34
Daiichi Sankyo Submits Application for Anti- hypertensive Drug Approval.....II-34
Mylan Receives FDA Approval for Nisoldipine Extended-Release.....II-34
Glenmark Wins FDA Approval for Trandolapril.....II-34
Novartis Obtains FDA Approval for Tekturna HCT.....II-34
Mylan Receives Tentative Approval for Generic Version of Benicar HCT.....II-34
1$100
   Novartis Secures Swissmedic Approval for Rasilez HCT.....II-35
Kyowa Secures Japanese Approval for Amlodipine Generic.....II-35
Aurobindo Pharma Obtains FDA Approval.....II-35
Actelion Receives EU Approval for Tracleer.....II-35
The Medicines Company Wins FDA Approval for Cleviprex.....II-35
Indian Pharmaceuticals Wins Approval for Propranolol Hydrochloride Tablets.....II-35
1$100
   Aurobindo Pharma Secures FDA Approval for Lotensin Generic.....II-36
Zydus Cadila Obtains FDA Approval for Marketing of Benazepril.....II-36
Mylan Wins FDA Approval for Mavik’s Generic.....II-36
Kampala Pharma to Commence Production of High Blood Pressure Drugs.....II-36
Merck Extends Licensing Agreement with AstraZeneca.....II-36
Helpson Receives China FDA Approval to Market Bumetanide Generic.....II-36
1$100
   Sciele Pharma Obtains FDA Approval.....II-37
DAIICHI SANKYO ILAÇ Acquires Anti-hypertensive Drug, Concor.....II-37
Novartis’ Rasilez HCT Receives European Committee Recommendation.....II-37
Pfizer Wins Patent Protection Lawsuit for Norvasc in Canada.....II-37
Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement.....II-37
Novartis Wins Canadian Approval for Rasilez.....II-37
1$100
   Hi-Tech Pharmacal Receives ANDA Approval from FDA.....II-38
Dr. Reddy's Receives FDA Approval for Trandolapril.....II-38
Quantum Genomics and PCAS Pharma Sign Strategic Agreement.....II-38
GeneraMedix Wins Approval from FDA for Epoprostenol.....II-38
1$100
   Pharmaceutical Holdings Changes Name to URL Pharma.....II-39
Zydus Cadila Obtains Approval from U.S. FDA for Ramipril Capsules.....II-39
Zydus Cadila Obtains Approval from U.S. FDA for Four Drugs.....II-39
KV Pharmaceutical Obtains FDA Approval for Toprol-XL Generic.....II-39
Ranbaxy Pharmaceuticals and AstraZeneca Sign Agreements.....II-39
1$100
   Recordati Completes Mutual Recognition with 28 European Nations.....II-40
Recordati Obtains Australian Approval for Zan-Extra®.....II-40
Santen Pharmaceutical Obtains Approval for TAPROS.....II-40
Santen Obtains Marketing Authorization for TAFLOTAN.....II-40
1$100
   Boehringer Ingelheim Wins EU Commission Approval for MicardisPlus® 80/25.....II-41
Daiichi Sankyo Europe Obtains Marketing Approval of SEVIKAR®.....II-41
Daiichi Sankyo Establishes Subsidiary in Ireland.....II-41
GlaxoSmithKline Wins EC Marketing Approval for Volibris.....II-41
NicOx Enters into Alliance with Royal DSM.....II-41
1$100
   NicOx Enters into Alliance with Archimica.....II-42
NicOx Enters into Alliance with Capsugel.....II-42
Novartis Obtains FDA Approval for Exforge and Diovan HCT.....II-42
Actelion and Merck Initiate Phase II Program Dosing, Reach Fourth Milestone.....II-42
1$100
   Jupiter Bioscience Acquires Drug Technology.....II-43
Recordati- Berlin Chemie Expand Licensing Agreement.....II-43
Meda and Recordati Enter into Agreement for Zaneril®.....II-43
Glenmark Wins FDA Approval for Coreg.....II-43
1$100
   Novartis Secures FDA Approval for Exforge.....II-44
Caraco Receives ANDA Approval for Norvasc Generic.....II-44
Mylan and Forest Labs Win FDA Approval to Market Bystolic.....II-44
Daiichi Sankyo Secures FDA Approval for Azor.....II-44
Teva Bags Approval to Market Accupril Generic.....II-44
Meda and Recordati Sign Long-Term Agreement.....II-44
1$100
   Ranbaxy Bags Approval to Produce and Market Amlodipine Besylate.....II-45
Caraco Receives FDA Approval for Atenolol Tablets.....II-45
Sciele Pharma and Addrenex Enter into Agreement.....II-45
Novartis Wins Swissmedic Approval for Tekturna.....II-45
1$100
   Lupin Bags Approval to Market Prinivil’s Generic Version.....II-46
Aurobindo Pharma Receives FDA Approval for Accuretic’s Generic Version.....II-46
Gilead Sciences Wins FDA Approval for Letairis.....II-46
Guangdong Luote Signs Agreement with Nippon Chemiphar.....II-46
Wockhardt Wins FDA Approval to Market Lisinopril.....II-46
1$100
   Kaken to Commence Marketing Procylin for Pulmonary Hypertension Treatment.....II-47
Encysive Pharma Wins Australian Approval for THELIN®.....II-47
Ranbaxy Wins Approval to Market Atenolol.....II-47
Novartis Secures EC Approval for Exforge.....II-47
1$100
   Ranbaxy Receives Health Canada Approval for Lisinopril Tablets.....II-48
Ranbaxy Receives Tentative Approval for Valsartan Tablets.....II-48
Bristol-Myers and sanofi-aventis Obtain FDA Approval for AVALIDE.....II-48
Par Pharmaceutical Receives FDA Approval for Propranolol HCl ER.....II-48
Ranbaxy Receives Approval from FDA for Coreg Generic.....II-48
1$100
   KV Pharmaceuticals Obtains FDA Approval for Toprol-XL Generic.....II-49
Mylan Wins Approval for Propranolol Hydrochloride ER Capsules.....II-49
Novartis Wins EU Approval for Rasilez.....II-49
Actavis Group Secures FDA Approval for Carvedilol Tablets.....II-49
Par Pharmaceuticals Ships ER Metoprolol Succinate Tablets.....II-49
1$100
   Biovail Reaches Settlement Agreement with Watson Pharmaceuticals.....II-50
Lexicon Genetics Announces Name Change.....II-50
1$100
   AstraZeneca PLC (UK).....II-51
Bayer AG (Germany).....II-51
1$100
   Biovail Corp. (Canada).....II-52
Boehringer Ingelheim GmbH (Germany).....II-52
Bristol-Myers Squibb Company (USA).....II-52
1$100
   Daiichi Sankyo Company, Limited (Japan).....II-53
Dr. Reddy's Laboratories Ltd. (India).....II-53
Forest Laboratories, Inc. (USA).....II-53
GlaxoSmithKline PLC (UK).....II-53
1$100
   Merck & Co., Inc. (USA).....II-54
Mylan, Inc. (USA).....II-54
1$100
   Novartis AG (Switzerland).....II-55
Pfizer, Inc. (USA).....II-55
1$100
   Ranbaxy Laboratories Limited (India).....II-56
Sanofi-aventis (France).....II-56
1$100
   Solvay Pharmaceuticals SA (Belgium).....II-57
Takeda Pharmaceutical Company Limited (Japan).....II-57
Teva Pharmaceutical Industries Limited (Israel).....II-57
1$100
   The Medicines Company (USA).....II-581$100
   Table 1: World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-591$350
   Table 2: World Historic Review Analysis for Anti-hypertensive Drugs by Geographic Region - US, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-601$350
   Table 3: World 15-Year Perspective for Anti-hypertensive Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for the US, Europe and Rest of World Markets for 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-611$350
   A. Market Analysis.....III-1
Hypertension - Prevalence.....III-1
¬¬¬¬¬ Table 4: Hypertension Prevalence Among Adults in the US by Age Group: 2005-2006 (includes corresponding Graph/Chart).....III-1
1$200
   Table 5: Hypertension Prevalence Among Adults in the US by Gender: 2005-2006 (includes corresponding Graph/Chart).....III-2

Table 6: Hypertension Prevalence Among Adults in the US by Race/ Ethnicity: 2005-2006 (includes corresponding Graph/Chart).....III-2

Table 7: Hypertension Treatment Among Hypertensive Adults in the US - Percentage Share Breakdown by Gender and Age Group: 2005-2006 (includes corresponding Graph/Chart).....III-2
1$200
   Table 8: Hypertension Treatment Among Hypertensive Adults in the US - Percentage Share Breakdown by Race/Ethnicity: 2005- 2006 (includes corresponding Graph/Chart).....III-3

Table 9: Outpatient Department Visit with Hypertension as Co-morbid Chronic Condition in the US - Percentage Share Breakdown by Age Group: 2006 (includes corresponding Graph/Chart).....III-3

Table 10: Outpatient Department Visits with Hypertension as Co-morbid Chronic Condition in the US - Percentage Share Breakdown by Gender: 2006 (includes corresponding Graph/Chart).....III-3
1$200
   Market Overview.....III-4
Table 11: US Anti-hypertensive Drugs Market - Sales and Percentage Share Breakdown by Leading Drugs in US$ Million Between October 2007 and October 2008 (includes corresponding Graph/Chart).....III-4
1$200
   Table 12: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Class of Drug Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-5

Table 13: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-5
1$200
   Table 14: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Angiotension Receptor Blockers (ARBs) Based on Total Prescriptions for 2007 (includes corresponding Graph/Chart).....III-6
New Patient Therapy Starts to Witness Slowdown.....III-6
Table 15: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Angiotensin II Receptor Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-6
1$200
   Table 16: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of ACE Inhibitors by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-71$200
   Table 17: US Anti-hypertensive Drugs Market - Percentage Share Breakdown of Calcium Channel Blockers by New Prescriptions for 2006, 2007 and 2008 (includes corresponding Graph/Chart).....III-81$200
   African Americans At Major Health Risk Due to Hypertension.....III-9
Research & Development.....III-9
1$75
   Product Launches.....III-102$100
   Strategic Corporate Developments.....III-1212$275
   Select Players.....III-242$100
   B. Market Analytics.....III-26
Table 18: US Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-26
1$200
   Table 19: US Historic Review Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-271$200
   A. Market Analysis.....III-28
Hypertension – Prevalence.....III-28
Non-Invasive Blood Pressure Monitoring on Growth Trajectory.....III-28
Regional Markets at a Glance.....III-28
United Kingdom.....III-28
Hypertension – Prevalence.....III-28
1$75
   Hypertension Treatment – Monotherapy and Combination Therapies.....III-29
Denmark.....III-29
Cheaper Alternatives for Hypertension Treatment.....III-29
Norway.....III-29
New Branded Drugs Dominate Anti- hypertensive Drugs Market.....III-29
New Amendments to Medicines Reimbursement.....III-29
1$75
   Proposed New Reimbursement Conditions in Norway.....III-301$75
   Research and Development.....III-311$75
   Product Launches.....III-322$100
   Strategic Corporate Developments.....III-344$150
   Select Players.....III-384$150
   B. Market Analytics.....III-42
Table 20: European Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-42
1$200
   Table 21: European Historic Review Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-431$200
   A. Market Analysis.....III-44
Canada.....III-44
Table 22: Canadian Anti-hypertensive Drugs Market - Total Number of Prescriptions in Thousands for 1996 and 2006 (includes corresponding Graph/Chart).....III-44
1$200
   Japan.....III-45
Australia.....III-45
Australians to Shell Out More on Anti- Hypertensive Drugs.....III-45
China.....III-45
Hypertension – A Major Health Concern in China.....III-45
1$75
   Anti-hypertensive Drugs Market.....III-46
Hypertension Outlook.....III-46
Competitive Landscape.....III-46
1$75
   India.....III-47
Anti-Hypertensive Drugs Manufacturers.....III-47
1$75
   Korea.....III-48
Anti-hypertensive Drugs Market.....III-48
Table 23: Korean Anti-hypertensive Drugs Market - Leading Classes of Drugs by Value Sales in US$ Million for 2007, 2008, and 2009 (Q1) (includes corresponding Graph/Chart).....III-48
1$200
   Table 24: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Drugs by Outpatient Prescription Value for 2007, 2008 and 2009 (H1) (includes corresponding Graph/Chart).....III-491$200
   Anti-hypertension Drugs Market – Angiotensin Receptor Blockers.....III-50
Table 25: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Angiotension Receptor Blockers by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-50
1$200
   Anti-hypertension Drugs Market – Calcium Channel Blockers.....III-51
Table 26: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Calcium Channel Blockers by Prescription Value for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-51
1$200
   Anti-hypertension Drugs Market – Beta-blockers.....III-52
Table 27: Korean Anti-hypertensive Drugs Market - Percentage Share Breakdown of Leading Beta-blockers for 2008 and 2009 (Q1) (includes corresponding Graph/Chart).....III-52
1$200
   Kenya.....III-53
Anti-hypertensive Drugs Market.....III-53
Manufacturing Overview.....III-53
Generics Erode Share of Ethical Drugs.....III-53
Research and Development.....III-53
1$75
   Product Launches.....III-542$100
   Strategic Corporate Developments.....III-567$175
   Select Players.....III-633$125
   B. Market Analytics.....III-66
Table 28: Rest of World Recent Past, Current & Future Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....III-66
1$200
   Table 29: Rest of World Historic Review Analysis for Anti-hypertensive Drugs - Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....III-671$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com